Evidence map›Paper›PMID 36786216›Full record

ArticleCirculation research2023

Deacetylation of Septin4 by SIRT2 (Silent Mating Type Information Regulation 2 Homolog-2) Mitigates Damaging of Hypertensive Nephropathy.

Ying Zhang, Naijin Zhang, Yuanming Zou, Chunyu Song, Kexin Cao, Boquan Wu, Shilong You, Saien Lu, Dong Wang, Jiaqi Xu and 9 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
3.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 43 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. [Wogonoside Attenuates Hypertension-Induced Renal Injury Through Modulation of the MAPK Signaling Pathway: A Mechanism Study].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2025
    Article
  18. Article
  19. Review
  20. Reactive oxygen species in hypertension.Nature reviews. Cardiology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 3 countries.

Ying Zhang *Department of Cardiology (Y.Z., N.Z., Y.Z., C.S., K.C., B.W., S.Y., S.L., D.W., J.X., X.H., P.Z., Z.F., Y.S.), the First Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China.ORCID 0000-0003-0962-7398
Naijin Zhang *Department of Cardiology (Y.Z., N.Z., Y.Z., C.S., K.C., B.W., S.Y., S.L., D.W., J.X., X.H., P.Z., Z.F., Y.S.), the First Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China.
Yuanming ZouDepartment of Cardiology (Y.Z., N.Z., Y.Z., C.S., K.C., B.W., S.Y., S.L., D.W., J.X., X.H., P.Z., Z.F., Y.S.), the First Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China.ORCID 0000-0002-0627-952X
Chunyu SongDepartment of Cardiology (Y.Z., N.Z., Y.Z., C.S., K.C., B.W., S.Y., S.L., D.W., J.X., X.H., P.Z., Z.F., Y.S.), the First Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China.ORCID 0000-0002-1845-8189
Kexin CaoDepartment of Cardiology (Y.Z., N.Z., Y.Z., C.S., K.C., B.W., S.Y., S.L., D.W., J.X., X.H., P.Z., Z.F., Y.S.), the First Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China.ORCID 0000-0001-6903-3896
Boquan WuDepartment of Cardiology (Y.Z., N.Z., Y.Z., C.S., K.C., B.W., S.Y., S.L., D.W., J.X., X.H., P.Z., Z.F., Y.S.), the First Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China.ORCID 0000-0002-4242-2821
Shilong YouDepartment of Cardiology (Y.Z., N.Z., Y.Z., C.S., K.C., B.W., S.Y., S.L., D.W., J.X., X.H., P.Z., Z.F., Y.S.), the First Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China.
Saien LuDepartment of Cardiology (Y.Z., N.Z., Y.Z., C.S., K.C., B.W., S.Y., S.L., D.W., J.X., X.H., P.Z., Z.F., Y.S.), the First Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China.ORCID 0000-0002-6033-5801
Dong WangDepartment of Cardiology (Y.Z., N.Z., Y.Z., C.S., K.C., B.W., S.Y., S.L., D.W., J.X., X.H., P.Z., Z.F., Y.S.), the First Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China.
Jiaqi XuDepartment of Cardiology (Y.Z., N.Z., Y.Z., C.S., K.C., B.W., S.Y., S.L., D.W., J.X., X.H., P.Z., Z.F., Y.S.), the First Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China.
Xinyue HuangDepartment of Cardiology (Y.Z., N.Z., Y.Z., C.S., K.C., B.W., S.Y., S.L., D.W., J.X., X.H., P.Z., Z.F., Y.S.), the First Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China.ORCID 0000-0001-8528-3465
Pengyu ZhangDepartment of Cardiology (Y.Z., N.Z., Y.Z., C.S., K.C., B.W., S.Y., S.L., D.W., J.X., X.H., P.Z., Z.F., Y.S.), the First Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China.
Zihao FanDepartment of Cardiology (Y.Z., N.Z., Y.Z., C.S., K.C., B.W., S.Y., S.L., D.W., J.X., X.H., P.Z., Z.F., Y.S.), the First Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China.
Jingwei LiuCollege of Basic Medical Science; Key Laboratory of Medical Cell Biology, Ministry of Education; Liaoning Province Collaborative Innovation Center of Aging Related Disease Diagnosis and Treatment and Prevention, Shenyang, Liaoning Province, China (J.L., L.C.).ORCID 0000-0003-3177-5821
Zhongyi ChengJingjie PTM BioLab Co. Ltd (Z.C.).ORCID 0000-0002-8764-2019
Zhe ZhangDepartment of Urology (Z.Z., C.K.), the First Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China.
Chuize KongDepartment of Urology (Z.Z., C.K.), the First Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China.
Liu CaoCollege of Basic Medical Science; Key Laboratory of Medical Cell Biology, Ministry of Education; Liaoning Province Collaborative Innovation Center of Aging Related Disease Diagnosis and Treatment and Prevention, Shenyang, Liaoning Province, China (J.L., L.C.).
Yingxian SunDepartment of Cardiology (Y.Z., N.Z., Y.Z., C.S., K.C., B.W., S.Y., S.L., D.W., J.X., X.H., P.Z., Z.F., Y.S.), the First Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China.ORCID 0000-0002-1961-899X
Zigong First People's Hospital · CNZunyi Medical University · CNFirst Hospital of China Medical University · CNMinistry of Education of the People's Republic of China · CNNew England Biolabs (China) · CNWorld Wide Web Consortium · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHypertension can lead to podocyte damage and subsequent apoptosis, eventually resulting in glomerulosclerosis. Although alleviating podocyte apoptosis has clinical significance for the treatment of hypertensive nephropathy, an effective therapeutic target has not yet been identified. The function of septin4, a proapoptotic protein and an important marker of organ damage, is regulated by post-translational modification. However, the exact role of septin4 in regulating podocyte apoptosis and its connection to hypertensive renal damage remains unclear.

methodsWe investigated the function and mechanism of septin4 in hypertensive nephropathy to discover a theoretical basis for targeted treatment. Mouse models including Rosa 26 (Gt(ROSA)26Sor)-

resultsUsing transgenic

conclusionsSeptin4, when activated through acetylation of K174 (K174Q), promotes hypertensive renal injury. Septin4-K174R, which mimics deacetylation by SIRT2, inhibits the cleaved-PARP1-cleaved-caspase3 pathway. Septin4-K174R acts as a renal protective factor, mitigating Ang II-induced hypertensive renal injury. These findings indicate that septin4-K174 is a potential therapeutic target for the treatment of hypertensive renal injury.

Indexed as

HypertensionHypertension, RenalAnimalsApoptosisHumansKidneyMiceMice, TransgenicNephritisProteomicsSeptinsSirtuin 2Sept4 protein, mouseSeptinsSIRT2 protein, humanSirtuin 2apoptosishypertensive nephropathypodocytesproteomicssirtuins

Identifiers

PMID36786216
PMCPMC9977266
OpenAlexW4320709953

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.